HematologyNews.net

Hematology Xagena

Search results for "Chronic lymphocytic leukemia"

The 84 percent of patients who had no detectable traces of chronic lymphocytic leukemia ( CLL ) after receiving Alemtuzumab had survived for at least 5 years. A study, led by Peter Hillmen from the ...


A case study by Mayo Clinic researchers provides preliminary evidence to suggest a component of green tea may lead to clinical improvement in patients with chronic lymphocytic leukemia ( CLL). Find ...


Lenalidomide ( Revlimid ) is safe and well-tolerated for elderly patients with chronic lymphocytic leukaemia ( CLL ), a group without a well-defined frontline therapy for their disease, researchers fr ...


Novel treatments have shown improvements in survival and response rates for leukemia and lymphoma. The use of Dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the ...


Genzyme Europe BV has informed Healthcare Professional of six infection-related deaths, reported from a trial ( CALGB10101 ) in which previously untreated, symptomatic B-cell chronic lymphocytic leuke ...


Lenalidomide ( Revlimid ) is safe and well-tolerated for elderly patients with chronic lymphocytic leukaemia ( CLL ), a group without a well-defined frontline therapy for their disease, researchers fr ...


The study enrolled patients with chronic lymphocytic leukemia ( CLL ), heavily pre-treated, who did not respond to, or who were ineligible for, currently available treatment options such as Fludarabin ...


Researchers at the Ohio State University have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.Their study has shown ...


GlaxoSmithKline ( GSK ) and Genmab have announced the results from the concluded pivotal trial of Ofatumumab ( Arzerra ) in patients with Fludarabine ( Fludara ) and Alemtuzumab ( Campath ) refractory ...


Ofatumumab ( Arzerra ) is a fully human monoclonal antibody that binds to both the large and small extracellular loops of CD20. Ofatumumab is currently approved for patients with refractory chronic ly ...


The first results from CLL11, a phase III study of the investigational medicine Obinutuzumab ( GA101; Gazyva ) were presented. The CLL11 study compared the combination of either GA101 or Rituximab ( M ...


Results from a phase 2 study ( Study 101-08 ) evaluating Idelalisib ( formerly GS-1101 ), an investigational, targeted, oral inhibitor of PI3K delta, in combination with Rituximab ( MabThera, Rituxan ...


Several new, targeted therapies show promise to expand treatment options for chronic lymphocytic leukemia ( CLL ) and are more effective and better tolerated than standard chemotherapy, according to s ...


Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ...


The Food and Drug Administration ( FDA ) has expanded the approved use of Imbruvica ( Ibrutinib ) for chronic lymphocytic leukemia ( CLL ) patients who have received at least one previous therapy.Chro ...